Skip to main content

Advertisement

Table 5 Common, all-causality adverse events reported in patients with OS ≥24 versus < 24 months in the axitinib titration arm

From: Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study

Adverse event,a n (%) OS ≥24 months n = 33 OS < 24 months n = 20b
All Grades Grade ≥ 3 All Grades Grade ≥ 3
Any 33 (100) 24 (73) 19 (95) 11 (55)
Diarrhoea 27 (82) 7 (21) 7 (35) 0
Hypertension 24 (73) 7 (21) 10 (50) 3 (15)
Fatigue 18 (55) 1 (3) 9 (45) 2 (10)
Nausea 14 (42) 1 (3) 10 (50) 2 (10)
Hand–foot syndrome 14 (42) 1 (3) 4 (20) 1 (5)
Hypothyroidism 14 (42) 0 4 (20) 0
Decreased appetite 12 (36) 2 (6) 8 (40) 2 (10)
Weight decrease 12 (36) 6 (18) 4 (20) 0
Vomiting 11 (33) 3 (9) 8 (40) 1 (5)
Dysphonia 11 (33) 0 7 (35) 1 (5)
Arthralgia 10 (30) 0 3 (15) 1 (5)
Stomatitis 10 (30) 1 (3) 0 0
Mucosal inflammation 9 (27) 1 (3) 3 (15) 1 (5)
Proteinuria 9 (27) 2 (6) 3 (15) 0
  1. Abbreviation: OS overall survival
  2. aReported by ≥25% in either group
  3. bExcluded 3 patients who were censored < 24 months in OS